This prospective, randomized, controlled study compared the effects of recombinant human FSH (r-hFSH) and highly purified urinary FSH (u-hFSH HP) on lipoprotein(a) [Lp(a)] concentrations in women undergoing ovarian stimulation. Fifty infertile women were randomly allocated into two equally sized treatment groups (n ⍧ 25 per group). Thirty normal ovulation women were recruited as controls. The infertile women received u-hFSH or r-hFSH 150 IU/day starting on cycle day 2. From cycle day 6 the dose was adjusted according to ovarian response. Human chorionic gonadotrophin 10 000 IU was administered once there was at least one follicle ≥18 mm in diameter. The luteal phase was supported with progesterone 50 mg/day for at least 15 days. Repeated measurements of Lp(a) concentrations were performed during both stimulated and natural cycles. A significant increase in luteal phase Lp(a) concentrations was detected in the stimulated cycles, whereas no significant changes in serum Lp(a) concentrations were observed during natural cycles. There were no significant differences between the urinary and recombinant FSH effects on serum Lp(a). The luteal Lp(a) increase was transitory because after 1 month Lp(a) concentrations returned to baseline values if pregnancy failed to occur; in pregnant women persistent increased Lp(a) concentrations were found at the 8th week. The percentage changes in serum Lp(a) were positively correlated with the luteal progesterone increase (r ⍧ 0.40, P < 0.05), but not with follicular or luteal oestradiol increase. The women with low baseline Lp(a) (≤5 mg/dl) had a greater increase of the Lp(a) concentrations at midluteal phase than women with baseline Lp(a) >5 mg/dl. In conclusion, the recombinant or urinary hFSH administration does not directly influence Lp(a) concentrations. The luteal Lp(a) increase in stimulated cycles is not related to gonadotrophin treatment per se, but appears to be related to the high luteal progesterone concentrations, physiologically or pharmacologically determined. Our results also suggest that the sensitivity to the progesterone changes could be related to apolipoprotein(a) phenotype.
Introduction
1993; Cantin et al., 1998) . In women, case-control studies (Dahlen et al., 1986; Labeur et al., 1992; Solymoss et al., Lipoprotein(a) [Lp(a) ], which was first described by Berg 1993; Farrer et al., 1994; Wang et al., 1994; Bolibar et al., (1963) , differs from low density lipoprotein by an additional 1995; Sunayama et al., 1996; Orth-Gomer et al., 1997) and a large protein, apoliprotein(a) [apo(a)], disulphide-linked to an prospective study (Bostom et al., 1994) have shown that Lp(a) apo B-100 apoprotein (Murai et al., 1986; Marcovina and is associated with coronary heart disease. Lp(a) concentrations Morrisett, 1995; White and Lanford, 1995) . Several studies are largely genetically determined, primarily by sequence have suggested that Lp(a) is a strong independent risk factor polymorphisms in the apo(a) gene lipoprotein (Boerwinkle both for ischaemic heart disease and for cerebrovascular et al., 1992; Lackner et al., 1993; Mooser et al., 1995) . disease (Uterman, 1989; Heinrich et al., 1991; Scanu, 1992;  However, there is evidence to suggest that previous genetic Cremer et Schaefer et al., 1994; Dahlen and Stenlund, studies may have underestimated the contribution of non-1997; Schwartzman et al., 1998) . Other prospective data have genetic factors to the variation in Lp(a) concentrations in the found no relation between Lp(a) and coronary heart disease, but these studies comprised only male subjects (Ridker et al., population (Maeda et al., 1989; Von Eckardstein et al., 1997) .
150 IU/day. From cycle day 6, dose adjustment was performed, Premenopausal women have lower Lp(a) concentrations than according to follicular development, as assessed by ultrasound postmenopausal women in cross-sectional studies (Heinrich scanning . Human chorionic gonadotrophin (HCG) 10 000 IU was Jenner et al., 1993; Kim et al., 1994) . Lp(a) administered to induce ovulation when at least one follicle ജ18 mm serum concentrations increase after a natural or surgical in diameter was present. The luteal phase was supported with 50 mg menopause (Heinrich et al., 1991; Meilahn, et al., 1991; et Haines et al., 1996; Kim et al., 1996; Hänggi Blood samples for measurement of serum Lp(a), oestradiol and et al Espeland et al., 1998; Spencer et al., 1999) .
progesterone, were taken from all subjects on cycle day 2 before No significant changes have been reported with the use of starting gonadotrophin administration, on cycle day 6, on the day of transdermal oestradiol, suggesting that the effects of orally HCG administration, and 10 days after HCG administration. In patients who failed to achieve pregnancy, Lp(a) serum concentration administered oestrogens may stem from their capacity to measurements were repeated on day 2 of the following menstruation, influence hepatic metabolic processes (Hänggi et al., 1997;  providing one month of wash-out. In patients who achieved pregnancy Spencer et al., 1999) . Few studies are available on Lp(a) measurements of Lp(a), oestradiol and progesterone serum concentrachanges in women undergoing ovarian stimulation (Seed et al., tions were repeated after a comparable period at the 8th week. In the Haines et al., 1997) ; these studies evaluated the control group, blood was collected on cycle day 2. FSH (r-hFSH) treatment on Lp(a) concentrations in a prospectEach blood sample was collected between 0800 and 0900 h after a 12 h fast.
ive randomized study.
Laboratory analyses

Materials and methods
Blood was taken from an antecubital vein with minimal stasis using Patients standard venepunture techniques into serum tubes. Serum samples Fifty infertile Caucasian women undergoing ovarian stimulation for were separated by centrifugation at 3000 g for 10 min and stored assisted reproduction were enrolled in the study between January and at -80°C until analysis. Each subject's sample was analysed in the December 1999. Inclusion criteria were: aged between 28 and 38 same assay to minimize interassay variation. All samples were tested years; normal ovulatory cycles; FSH, LH, prolactin, testosterone-free for Lp(a), 17β-oestradiol and progesterone concentrations. Lp(a) and dehydroepiandrosterone sulphate within normal range on cycle measurements were determined by means of a commercial enzymeday 3; primary infertility due to unexplained factor or male factor; linked immunosorbent assay kit (Macra ® Lp(a) manufactured by no previous treatment with clomiphene citrate, gonadotrophins, sexual Strategic Diagnostics Inc. for Trinity Biotech USA, Jamestown, NY, steroids or drugs known to influence lipoprotein metabolism. USA); the test is a sandwich assay which utilizes both a monoclonal Exclusion criteria included: chronic diseases, body mass index antibody and polyclonal antibodies which specifically bind to the Ͻ18 or Ͼ27 kg/m 2 ; past or current abuse of alcohol; Ͼ5 cigarettes apolipoprotein (a) moiety of Lp(a). All samples were run in duplicate per day; regular intake of drugs.
and the results were expressed in mg/dl; the intra-and interassay Thirty comparable volunteer Caucasian nulliparous women were coefficients of variation for this method were Ͻ5% and Ͻ10% concurrently recruited as controls. Inclusion criteria were: aged respectively. Serum 17β-oestradiol and progesterone were determined between 28 and 38 years; regular menstrual cycles lasting from 26 by means of a solid-phase, ligand-labelled, competitive chemiluminesto 30 days; previous three cycles of regular length; no administration cent immunoassay with an Immulite Analyzer (Immulite ® Estradiol of sex steroids or drugs known to affect lipid metabolism within the and Immulite ® Progesterone, Diagnostic Products Corporation, Los previous 12 months. The exclusion criteria were the same as for Angeles, CA, USA) and results were expressed in pg/ml and ng/ml infertile subjects.
respectively.
Study design Statistical analyses
This was an open, randomized, controlled study comparing the Given the skewed Lp(a) distribution, non-parametric statistics were effect of u-hFSH and r-hFSH on Lp(a) serum concentrations. After used to protect against non-normal distribution of data. Statistical confirming eligibility for the study, the infertile women were randomly analyses of all baseline parameters for between-group differences allocated into two equally sized treatment groups (n ϭ 25 per group)
were performed by means of Kruskal-Wallis analysis of variance using a random number generator on a personal computer. Thirty (ANOVA) test. The χ 2 -test was used to compare categorized measures non-randomized, comparable women were included in the untreated when appropriate. Multiple comparisons of paired data during natural control group. Informed consent was obtained from each subject and stimulated cycles were performed with Friedman's repeated before the start of the study. The study was conducted in accordance measures test followed by Dunn's multiple comparisons post-hoc test. with the guidelines proposed in The Declaration of Helsinki. Statistically significant differences between the stimulated and control Study protocol groups were examined by the Mann-Whitney U-test. Spearman's rank correlation coefficient was used to assess correlations between Starting on cycle day 2, infertile patients received u-hFSH (Metrodin HP; Serono, Rome, Italy) or r-hFSH (Gonal F; Serono, Rome, Italy) parameters. Statistical significance was assigned when P Ͻ 0.05. r-hFSH ϭ recombinant human follicle stimulating hormone; u-hFSH HP ϭ urinary human FSH; NS ϭ not significant.
Results
No significant differences were seen between the three groups (Table I ). The infertility characteristics of the two treatment different time points. I ϭ baseline; II ϭ cylce day 6; III ϭ human groups were not significantly different (Table II) . There were chorionic gonadotrophin day; IV ϭ midluteal. Friedman repeated measures test: controls, not significant; recombinant human (rno significant differences in the stimulation characteristics of h)FSH, P Ͻ 0.001; urinary human (u-h)FSH, P Ͻ 0.01.
the patients receiving HCG (Table III) . The pregnancy rate cycle was 24% for r-hFSH and 20% for u-hFSH (not significantly different). In the control group two subjects had an (r ϭ -0.28; P Ͼ 0.05) or at midluteal phase (r ϭ 0.07; P Ͼ 0.05). There was a positive correlation between the anovulatory cycle and were excluded from the analysis. No significant changes in serum Lp(a) concentrations during the percentage changes (versus baseline) in serum Lp(a) concentrations and the increase in serum progesterone at midluteal phase different phases of the menstrual cycle were observed in the control group, whereas a significant increase in luteal phase (r ϭ 0.40, P Ͻ 0.05) (Figure 4) . To evaluate the sensitivity of Lp(a) to progesterone increase, we divided the treatment Lp(a) concentrations was detected in the stimulated women (Table IV, Figure 1 ). There were no significant differences group into two subgroups classified according to a baseline serum Lp(a) lower (n ϭ 24) or higher (n ϭ 24) than 5 mg/dl. between the urinary and recombinant FSH effects on serum Lp(a) (Figure 2 ). The luteal Lp(a) increase can be considered
There was a significant correlation between the percentage changes of the Lp(a) concentrations (versus baseline) and the transitory because after 1 month Lp(a) concentrations returned to baseline values if pregnancy failed to occur; in pregnant midluteal progesterone increase in women with baseline Lp(a) Ͻ5 mg/dl (r ϭ 0.60, P Ͻ 0.05) (Figure 5 ), but not in women women (n ϭ 11) persistently increased Lp(a) concentrations were found at the 8th week (Figure 3 ). The percentage with baseline Lp(a) Ͼ5 mg/dl (r ϭ 0.25, P Ͼ 0.05) ( Figure  6 ). Furthermore, although the midluteal progesterone mean changes (versus baseline) in serum Lp(a) were not significantly correlated with the increase in serum oestradiol on HCG day concentrations were not statistically different, the percentage 1970s, urinary-derived gonadotrophin preparations contained FSH in combination with LH whereas later purified FSH (with changes (versus baseline) in serum Lp(a) concentrations at Ͻ1% LH contamination) or highly purified FSH (with Ͻ0.1% midluteal phase were greater in women with baseline Lp(a) LH contamination) were introduced. Recently, 99% pure FSH Ͻ5 mg/dl than in women with baseline Lp(a) Ͼ5 mg/dl preparations produced by recombinant DNA technology have (Figure 7) . become available. Recombinant technology ensures there is no LH activity and no contaminating urinary proteins of Discussion undetermined origin (Olijve et al., 1996) . Previous studies, aimed at assessing whether gonadotrophin administration can Although the number of women who undergo ovarian stimulaadversely affect cardiovascular risk, evaluated changes in Lp(a) tion with gonadotrophins has grown rapidly in the last 20 years, serum concentrations during ovarian stimulation (Seed et al., the long-term effects of these treatments have not been fully addressed. Furthermore, during these years, different 1990, 1991; Haines et al., 1997) . Lp(a), in fact, has been going ovarian stimulation, the effects of HMG administration (Seed et al., 1990 (Seed et al., , 1991 were evaluated. An increase, albeit not statistically significant, probably because of the low number of subjects investigated, in Lp(a) median concentration from 3 to 9 mg/dl and from 6.4 to 7.9 mg/dl at the end of the HMG administration was observed. Unfortunately, luteal Lp(a) changes were not considered, thus the whole effect of HMG administration could not be evaluated.
In this study, we have shown that FSH administration does not directly influence serum Lp(a) concentrations. No increase in Lp(a) concentrations was observed during the follicular phase of r-hFSH or u-hFSH stimulated cycles. The different effects of HMG and uFSH on Lp(a) might be due to the LH content of HMG. In hypogonadotrophic women, HMG (Couzinet et al., 1988) . However, with baseline Lp(a) Ͻ5 mg/dl. no conclusive data regarding androgen influence on Lp(a) concentrations are available. No significant correlations were found between Lp(a) and testosterone concentrations in myocardial infarction patients and healthy controls (MarquesVidal et al., 1995) . In normal men, parenteral testosterone reduced Lp(a) concentrations (Zmuda et al., 1996) , whereas, in males suffering from prostatic carcinoma, parenteral testosterone administration lowered Lp(a) concentrations by 20%, while orchidectomy increased Lp(a) concentrations by 20% (Henriksson et al., 1992; Berglund et al., 1996) . In patients with hypogonadism Lp(a) concentrations did not change significantly following parenteral testosterone or gonadotrophin treatment (Ozata et al., 1996) . No data have been reported on the relationship between Lp(a) and androgens in women. Alternatively, gonadotrophin-releasing hormone (GnRH) analogue administration before starting HMG treatment might associated with a pronounced increase in Lp(a) concentrations (Von Eckardstein et al., 1997) , although buserelin reduced concentrations of Lp(a) by 48% in elderly males suffering from cancer of the prostate (Arrer et al., 1996) . Unfortunately, in Seed's studies (Seed et al., 1990 (Seed et al., , 1991 Lp(a) serum concentrations prior to GnRH analogue administration were not evaluated. Haines et al. (1997) reported an increased concentration of Lp(a) in the luteal phase of natural and HMG-stimulated cycles, suggesting that progesterone may cause an increase in Lp(a) serum concentrations. This conclusion, however, was speculative, as the design of this study did not allow for evaluation of the separate effects of increased progesterone and oestrogen concentrations on Lp(a) concentrations. Since only two blood samplings, in the late midfollicular and midluteal phases, were performed, and no base data were II ϭ cylce day 6; III ϭ human chorionic gonadotrophin day; IV ϭ midluteal. *P Ͻ 0.05 (Mann-Whitney U-test).
Our data on stimulated cycles demonstrated that Lp(a) increases only when progesterone is raised. There were no significant changes in Lp(a) concentrations at the end of reported to be an independent risk factor both for ischaemic heart disease and for peripheral vascular disease.
the follicular phase, even when very high concentrations of oestrogens were present. In two small series, respectively 22 and 20 women under-Furthermore, the luteal increase in Lp(a) concentrations shown that medroxyprogesterone acetate (MAP) and norgestrel attenuated the Lp(a)-lowering effect of oestrogen (Kim et al. , in stimulated cycles was statistically correlated with luteal progesterone increase, but not with follicular or luteal oestradiol 1996). On the contrary, in the PEPI trial, no significant differences were apparent between CEE only and each comincrease. We found that Lp(a) concentrations did not significantly change during the natural cycle. This finding is consistent bination regimen with MAP or micronized progesterone (Espeland et al., 1998) . with a previous study (Owens et al., 1993) but not with Haines' data (Haines et al., 1997) . Haines' study, however,
The results of this study demonstrated that urinary and recombinant FSH administration had similar effects on Lp(a) has many limitations, such as a low number of blood samples during the menstrual cycle, or the lack of blood sample concentrations. If no pregnancy occurred, we found that after 1 month Lp(a) concentrations fell to pre-treatment values, timing standardization. Therefore, we are led to conclude that progesterone only at supraphysiological concentrations suggesting that the effect of ovarian stimulation with u-hFSH or r-hFSH was transitory and the 4-week wash-out period was significantly influences Lp(a) concentrations. However, we cannot rule out that some phenotypes have different responses probably sufficient to eliminate any residual drug influence.
In women who have conceived, Lp(a) concentrations remained to menstrual cycle progesterone changes. Alternatively, the luteal Lp(a) increase could be related to a pharmacological elevated. We cannot demonstrate whether an Lp(a) increase normally occurs during pregnancy or whether it was related effect of the parenteral progesterone administration. Tonolo et al. (1995) in a small but well-designed study, considering to ovarian stimulation and/or parenteral progesterone administration. Few data are currently available on Lp(a) changes only women with an ovulatory cycle, showed a significant luteal apo(a) increase in four cases, whereas no significant during spontaneous pregnancy and no study has evaluated Lp(a) concentrations before and after conceiving. Zechner changes were detected in the remaining 11 cases. The four women with an increase of apo(a) had only S4 bands on et al. (1986) showed that Lp(a) concentrations rose steadily during the first trimester of pregnancy. However, this study sodium dodecyl sulphate-polyacrylamide gel electrophoresis. Furthermore, these women had lower plasma mean concentradid not evaluate Lp(a) concentrations before the eighth week; furthermore, Lp(a) was measured by the Laurell technique, a tions (8 U/dl) compared to the 11 women who showed no significant apo(a) change (54 U/dl). Indeed, an inverse method with unacceptable analytical sensitivity. Recently, Sattar et al. (2000) reported a significant increase in Lp(a) correlation between apparent molecular weight and plasma concentrations of apo(a) has previously been reported, i.e. small values in normal pregnancy between 10 and 35 weeks. Other authors (Panteghini and Pagani, 1991) observed no significant apo(a) phenotypes are associated with high concentrations of Lp(a), and large apo(a) phenotypes are associated with low differences between Lp(a) concentrations in non-pregnant controls and pregnant women before the eighth week of concentrations of Lp(a) (Scanu and Fless, 1990; Boerwinkle et al., 1992; Lackner et al., 1993; Rader et al., 1993; Rader gestation. On the other hand, in stimulated cycles progesterone concentrations far exceed those in the natural cycle because et Querfeld et al., 1999) . Thus Tonolo's data (Tonolo et al., 1995) suggested that in women with alleles coding high of the presence of multiple corpora lutea and the luteal phase progesterone supplementation. molecular weight apo(a), the synthesis of apo(a) could be stimulated by progesterone. In our study we found that women
In conclusion, the administration of recombinant or urinary h-FSH does not directly influence Lp(a) concentrations. The with low baseline Lp(a) (Ͻ5 mg/dl) had a greater increase in Lp(a) concentrations at midluteal phase than women with total effects of ovarian stimulation with urinary and recombinant FSH on Lp(a) are comparable and are not related to baseline Lp(a) Ͼ5 mg/dl, providing further evidence that there is a different sensitivity of the apo(a) phenotypes to gonadotrophin preparations, but appear to be related to the high luteal progesterone concentrations, physiologically or progesterone changes.
We are unable to explain why progesterone should increase pharmacologically induced. The luteal Lp(a) increase in stimulated cycles is transitory. Therefore in women undergoing Lp(a) concentrations. Previous studies suggest that the effects of progestogens on Lp(a) concentrations are dependent on the ovarian stimulation using the currently available FSH preparations, the cardiovascular risk as assessed by Lp(a) is not dose and degree of androgenicity of the preparation employed. Consistent reductions in Lp(a) concentrations were observed significantly affected. in patients treated with norethisterone alone at doses of 10 mg/day (Farish et al., 1991) , and, to a lesser extent, when administered at 1 mg/day in combination with oestradiol
